Abstract
Drug-resistant tuberculosis (DR-TB) continues to be a public health problem. The emergence of resistance to antitubercular drugs, particularly those for treatment of DR-TB, has complicated the treatment with prolonged duration, and a higher risk of adverse effects (AEs). Introduction of newer drugs in DR-TB treatment regimens, co-morbid conditions, concomitant drugs and specific populations, increase the risk of previously unrecognized AEs and can contribute to unfavorable treatment outcomes. The Pharmacovigilance programme of India (PvPI) has been focusing on monitoring and management of ADRs associated with bedaquiline and delamanid along with other anti-tubercular drugs. This article will discuss the need, process of monitoring of adverse events for these drugs in India and a need to increase awareness among the general public.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call